Protagenic Therapeutics, Inc.\new (PTIX)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$2.8M
Stockholders' Equity
$1.7M
Cash & Equivalents
$565,985
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Protagenic Therapeutics, Inc.\new reported net income of -$963,616 and total assets of $2.8M. Every figure below is taken directly from Protagenic Therapeutics, Inc.\new's SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2020–FY2026 · as reported

$1.4M-$2.1M-$5.5M
FY2020FY2022FY2024FY2026
Revenue$0Net income$1.4M
FY2020 revenue
$0
FY2026 revenue
$0

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2026$0$1.4M
FY2025$0-$3.6M
FY2024$0-$5.5M
FY2023$0-$5.0M
FY2022$0-$3.6M
FY2021$0-$4.5M
FY2020$0-$2.5M
FY2019—-$1.8M
FY2018—-$2.6M
FY2017—-$2.3M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KAug 20, 2026on EDGAR ↗
10-QAug 19, 2026on EDGAR ↗
NT 10-QAug 14, 2026on EDGAR ↗
10-KAug 14, 2026on EDGAR ↗
NT 10-KJun 30, 2026on EDGAR ↗
8-KApr 7, 2026on EDGAR ↗
10-QMar 9, 2026on EDGAR ↗
8-KMar 3, 2026on EDGAR ↗
8-KFeb 24, 2026on EDGAR ↗
NT 10-QFeb 18, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$2.8Msource ↗
Stockholders’ Equity$1.7Msource ↗
Cash & Equivalents$565,985source ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue—source ↗
Net Income-$963,616source ↗
Operating Income-$961,247source ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$109,925source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.53source ↗
EPS (basic)$-0.53source ↗
Shares Outstanding1.8Msource ↗
Cash from Operations-$944,298source ↗
Cash from Financing—source ↗
Cash from Investing—source ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
7
Sells
0
Net shares
+73.5K

Restatement history

Point-in-time

2 of 275 annual fact-keys were materially restated between filings: what Protagenic Therapeutics, Inc.\new first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches PTIX’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/PTIX

MCP tool: get_sec_fundamentals ticker=PTIX

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/PTIX/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=PTIX as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/PTIX/history

MCP tool: get_fundamentals_history ticker=PTIX

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/PTIX

MCP tool: get_financial_health ticker=PTIX

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.